Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1992 Jun 01;79(11):3067-70 PMID: 1586748

Pubmed ID



Philadelphia chromosome (Ph1)-positive acute lymphoblastic leukemia (ALL) has a poor prognosis when treated with conventional chemotherapy. We analyzed the outcome of 67 HLA-identical sibling bone marrow transplants (BMTs) for Ph1-positive ALL reported to the International Bone Marrow Transplant Registry (IBMTR). Twenty-one of 67 (31%) transplant recipients survived in continuous complete remission more than 2 years after transplant. Two-year actuarial probabilities (95% confidence interval) of leukemia-free survival were 38% (23% to 55%) for 33 patients transplanted in first remission, 41% (23% to 61%) for 22 patients transplanted after relapse, and 25% (9% to 53%) for 12 patients failing to achieve remission with conventional chemotherapy. These data indicate that transplants are effective treatment for Ph1-positive ALL.

Author List

Barrett AJ, Horowitz MM, Ash RC, Atkinson K, Gale RP, Goldman JM, Henslee-Downey PJ, Herzig RH, Speck B, Zwaan FE


Mary M. Horowitz MD, MS Center Director, Professor in the Medicine department at Medical College of Wisconsin


2-s2.0-0026636931   175 Citations

MESH terms used to index this publication - Major topics in bold

Bone Marrow Transplantation
Child, Preschool
Graft vs Host Disease
Middle Aged
Neoplasm Recurrence, Local
Philadelphia Chromosome
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Remission Induction
jenkins-FCD Prod-321 98992d628744e349846c2f62ac68f241d7e1ea70